stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Navin Fluorine International Limited

India · NSE: NAVINFLUOR.NS · Market cap: · P/E: · P/S:

Navin Fluorine makes specialty fluorine chemicals, refrigerant gases, and provides contract development and manufacturing services for pharmaceutical and agricultural companies.

Navin Fluorine is one of India's oldest and largest fluorine chemistry companies. You may not think about fluorine much, but it's in a surprising number of things you use every day: the refrigerant that keeps your air conditioner cold, the active ingredient in certain medicines, and the chemicals that protect crops from pests. Navin Fluorine makes these kinds of molecules and sells them to other companies who turn them into finished products.

The company runs three main businesses. The first is specialty fluorochemicals — complex, high-value molecules that go into things like pharmaceuticals, agrochemicals, and performance materials. The second is refrigerant gases, the stuff that makes air conditioners and refrigerators work. The third, and increasingly the most exciting for investors, is CDMO — contract development and manufacturing. This means big drug and pesticide companies hire Navin Fluorine to develop and manufacture the special fluorine-containing ingredients they need, rather than building that capability themselves. The CDMO business is the growth engine. Making fluorine-based chemicals is hard — it requires specialized equipment, deep expertise, and strict safety protocols. Navin Fluorine has been doing this since the 1960s, and that experience is hard to replicate. Global pharma and agrochemical companies pay Navin Fluorine to handle the tricky chemistry so they can focus on what they do best: discovering new drugs and selling them.


The company is headquartered in Mumbai, India, and its shares trade on the National Stock Exchange. It has invested heavily in expanding its CDMO capabilities and building new plants, betting that the outsourcing trend in pharmaceuticals will keep growing. The risk is that this business is lumpy — contracts can be delayed, and customers can be demanding — but the long-term tailwind from companies wanting to outsource complex manufacturing is real.

Saved answer · last researched 16 Nov 2026